AliveCor

Executive Summary

AliveCor is a leading digital health company specializing in FDA-cleared, medical-grade personal electrocardiogram (EKG) devices under the Kardia brand. Founded in 2011 and headquartered in Mountain View, California, the company enables consumers to record and analyze heart rhythms directly on their smartphones using portable hardware and a software platform. AliveCor operates at the intersection of consumer electronics and clinical-grade diagnostics, serving both individual users and healthcare providers. Its subscription-based data services provide ongoing heart health monitoring, positioning the company well in the rapidly growing remote patient monitoring market. With increasing awareness of cardiovascular disease and the shift toward proactive health management, AliveCor's products have gained significant traction among consumers and physicians alike. AliveCor's growth is driven by its strong brand recognition, FDA-cleared offerings, and expanding ecosystem of AI-powered analytics. The company differentiates itself through its proprietary algorithms for detecting arrhythmias such as atrial fibrillation, which is the leading cause of stroke. While privately held and lacking disclosed financials, AliveCor's strategic partnerships with health systems and insurers suggest robust recurring revenue from subscriptions. The company faces competition from Apple's ECG feature and other wearable ECG devices, but its dedicated form factor and clinical validation provide a competitive edge. Future growth hinges on expanding its diagnostic capabilities, entering new markets, and deepening integration with healthcare workflows. AliveCor remains a compelling player in the digital health space with significant upside potential.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance of next-generation algorithm for expanded arrhythmia detection75% success
• H2 2026Major partnership with a national telehealth provider or health system50% success
• Q1 2027Launch of a new wearable form factor, such as a continuous monitoring patch60% success